Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: a multicenter DKTK/ROG analysis
Background and purpose - Reirradiation (reRT) is a valid option with considerable efficacy in patients with recurrent high-grade glioma, but it is still not known which patients might be optimal candidates for a second course of irradiation. This study validated a newly developed prognostic score in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
9 February 2018
|
| In: |
Radiotherapy and oncology
Year: 2018, Volume: 127, Issue: 1, Pages: 121-127 |
| ISSN: | 1879-0887 |
| DOI: | 10.1016/j.radonc.2018.01.011 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.radonc.2018.01.011 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0167814018300331 
|
| Author Notes: | Maximilian Niyazi, Sebastian Adeberg, David Kaul, Anne-Laure Boulesteix, Nina Bougatf, Daniel F. Fleischmann, Arne Grün, Anna Krämer, Claus Rödel, Franziska Eckert, Frank Paulsen, Kerstin A. Kessel, Stephanie E. Combs, Oliver Oehlke, Anca-Ligia Grosu, Annekatrin Seidlitz, Annika Lattermann, Mechthild Krause, Michael Baumann, Maja Guberina, Martin Stuschke, Volker Budach, Claus Belka, Jürgen Debus |
| Summary: | Background and purpose - Reirradiation (reRT) is a valid option with considerable efficacy in patients with recurrent high-grade glioma, but it is still not known which patients might be optimal candidates for a second course of irradiation. This study validated a newly developed prognostic score independently in an external patient cohort. - Material and methods - The reRT risk score (RRRS) is based on a linear combination of initial histology, clinical performance status, and age derived from a multivariable model of 353 patients. This score can predict post-recurrence survival (PRS) after reRT. The validation dataset consisted of 212 patients. - Results - The RRRS differentiates three prognostic groups. Discrimination and calibration were maintained in the validation group. Median PRS times in the development cohort for the good/intermediate/poor risk categories were 14.2, 9.1, and 5.3months, respectively. The respective groups within the validation cohort displayed median PRS times of 13.8, 8.8, and 3.8months, respectively. Uno’s C for development data was 0.64 (CI: 0.60-0.69) and for validation data 0.63 (CI: 0.58-0.68). - Conclusions - The RRRS has been successfully validated in an independent patient cohort. This linear combination of three easily determined clinicopathological factors allows for a reliable classification of patients and may be used as stratification factor for future trials. |
|---|---|
| Item Description: | Gesehen am 04.12.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1879-0887 |
| DOI: | 10.1016/j.radonc.2018.01.011 |